Key Client Fiduciary Advisors’s Cytosorbents CTSO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,923
Closed -$29.3K – 233
2026
Q2
$29.3K Hold
3,923
– – 0.01% 229
2026
Q1
$44.4K Hold
3,923
– – 0.02% 211
2025
Q4
$50.2K Hold
3,923
– – 0.02% 211
2025
Q3
$73.3K Hold
3,923
– – 0.02% 220
2025
Q2
$100K Hold
3,923
– – 0.04% 202
2025
Q1
$78.5K Buy
3,923
+2,195
+127% +$46.3K 0.04% 188
2024
Q4
$31.4K Hold
1,728
– – 0.01% 193
2024
Q3
$51.8K Hold
1,728
– – 0.02% 198
2024
Q2
$24.3K Hold
1,728
– – 0.01% 189
2024
Q1
$32.8K Buy
1,728
+1,128
+188% +$22K 0.02% 182
2023
Q4
$13.3K Sell
600
-50
-8% -$1.48K 0.01% 171
2023
Q3
$24.4K Buy
650
+50
+8% +$2.87K 0.02% 168
2023
Q2
$43.1K Hold
600
– – 0.03% 174
2023
Q1
$40.4K Hold
600
– – 0.03% 164
2022
Q4
$18.6K Hold
600
– – 0.01% 158
2022
Q3
$16K Hold
600
– – 0.01% 109
2022
Q2
$26K Buy
+600
New +$27.6K 0.03% 111

Other funds holding CTSO

Key Client Fiduciary Advisors's CTSO Position: Q3 2026 in Review

Key Client Fiduciary Advisors sold out of Cytosorbents (CTSO) in Q3 2026, closing a stake of 3,923 shares — an estimated $29.3K sold.

Key Client Fiduciary Advisors first reported a position in CTSO in Q2 2022 and held it in 17 quarters. The position peaked at $100K in Q2 2025. 28 funds tracked by Wall St. Rank hold CTSO as of Q3 2026.

  • Key Client Fiduciary Advisors reported no remaining Cytosorbents position as of Q3 2026 after selling out during the quarter.
  • Key Client Fiduciary Advisors sold 3,923 Cytosorbents shares in Q3 2026, an estimated $29.3K.
  • Key Client Fiduciary Advisors first reported a position in Cytosorbents in Q2 2022 and held it in 17 quarters.
  • Key Client Fiduciary Advisors's Cytosorbents position peaked at $100K in Q2 2025.
  • 28 funds tracked by Wall St. Rank held Cytosorbents as of Q3 2026.

Based on Key Client Fiduciary Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.